NCT00477282 - Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | Biotech Hunter

Enrollment

509

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Ovarian Cancer

Interventions

DRUG

Karenitecin

Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)

DRUG

Topotecan

Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)

Trial Locations (48)

1032

Budapest

1082

Budapest

1088

Budapest

9024

Győr

50009

Kaunas

92288

Klaipėda

163045

Arkhangelsk

167904

Syktyvkar

185007

Petrozavodsk

191104

Saint Petersburg

198255

Saint Petersburg

200535

Craiova

305035

Kursk

350040

Krasnodar

354057

Sochi

355047

Stavropol

357502

Pyatigorsk

390011

Ryazan

392013

Tambov

400015

Cluj-Napoca

410159

Oradea

413115

Engel's

426009

Isvesk

450054

Ufa

455001

Magnitogorsk

460021

Orenburg

500098

Bucharest

540072

Târgu Mureş

550245

Sibiu

600020

Vladimir

603109

Nizhny Novgorod

630108

Novosibirsk

670047

Ulan-Ude

679016

Birobidzhan

680042

Khabarovsk

690105

Vladivostok

700106

Iași

720237

Suceava County

82-300

Elblag

31-501

Krakow

20-090

Lublin

10-228

Olsztyn

45-060

Oploe

60-535

Poznan

61-866

Poznan

70-111

Szczecin

33-100

Tarnów

022328

Bucharest